奥曲肽逆转肝细胞肝癌多药耐药的机制

目的 探讨生长抑素（SST）类似物奥曲肽逆转肝癌细胞多药耐药可能的机制。方法 应用MTT法分析肝癌细胞对化疗药物的敏感性；RT—PCR、流式细胞术检测肝癌细胞多药耐药基因多药耐药糖蛋白1（MDR1）、多药耐药相关蛋白2（MRP2）mRNA及其蛋白质的表达。结果 奥曲肽联合化疗药物可以显著降低化疗药物的IC50肝癌细胞有生长抑索受体2（SSTR2）、生长抑素受体3（SSTR3）、MDR1、MRP2的表达，奥曲肽可显著降低肝癌细胞表面MDR1、MRP2的表达。结论 SST可与肝癌细胞表面的SSTR结合，降低其表面MDR2、MRP2的表达，使细胞内细胞毒药物浓度增加，从而逆转肝癌细胞多药耐药。

Mechanism of octreotide reverses multidrug resistance in hepatocellular carcinoma

[Objective] To investigate the possible mechanism of octreotide reverses multidrug resistance and the effect of octreotide chemosensitizes hepatoma cells. [Methods] The expression of the MDR1, MRP2 mRNA and protein were analyzed by RT-PCR and flow cytometer respectively. The cytotoxic effect of epirubincin, carboplatin, hydroxyl-camptothecin and 5-fluorouracil was analyzed by MTT assay. [Results] The 50% inhibitory concentration of cytotoxic agents was significantly reduced when combination with octreotide. There were SSTR2, SSTR3, MDR1 and MRPz expression in hepatoma cells, the expression of MDR1 and MRP2 on the surface of hepatoma cells reduced significantly after octreotide treatment. [Conclusions] Octreotide can chemosensitize hepatoma cells by inhibiting the expression of the MDR1 and MRP2 gene on the surface of hepatoma cells.